NCT07340164 2026-04-20
TROY
Yonsei University
Phase 2 Recruiting
Clinical Trials
21 trialsNCT05797246 2026-04-14
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT01356290 2026-02-23
MEMMAT
Medical University of Vienna
Phase 2 Recruiting
NCT07263438 2026-02-13
Phenix
Centre Hospitalier Universitaire Vaudois
Phase 2 Recruiting
NCT04868708 2025-03-04
A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
Akeso
Phase 2 Completed
NCT06801730 2025-01-30
NALIRIBVRG
The Central Hospital of Lishui City
Phase 2 Recruiting
NCT04739670 2024-03-01
BELLA
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT06041490 2023-09-18
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT03713944 2023-03-01
Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Terminated
NCT04015739 2022-08-17
BOLD
ARCAGY/ GINECO GROUP
Phase 2 Unknown
NCT02337491 2020-12-22
Pembrolizumab +/- Bevacizumab for Recurrent GBM
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01967810 2020-02-25
ANG1005 in Patients With Recurrent High-Grade Glioma
Angiochem Inc
Phase 2 Completed
NCT01498328 2020-02-17
ReACT
Celldex Therapeutics
Phase 2 Completed
NCT01782976 2018-01-19
Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01031381 2016-08-30
RADBEV
University of Pittsburgh
Phase 2 Completed
NCT02060955 2016-06-06
Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan
CytoVac A/S
Phase 2 Terminated
NCT01113398 2015-12-10
AMG 102 and Avastin for Recurrent Malignant Glioma
Duke University
Phase 2 Completed
NCT00271609 2014-04-29
Bevacizumab for Recurrent Malignant Glioma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00356122 2011-10-17
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Sanofi
Phase 2 Completed
NCT00463203 2011-06-29
Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy
Rigshospitalet, Denmark
Phase 2 Completed
NCT00095225 2008-01-29
A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)
Genentech, Inc.
Phase 2 Completed